> top > docs > PubMed:20215531 > annotations

PubMed:20215531 JSONTXT

Annnotations TAB JSON ListView MergeView

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-77 Sentence denotes Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
TextSentencer_T2 78-86 Sentence denotes PURPOSE:
TextSentencer_T3 87-241 Sentence denotes Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined.
TextSentencer_T4 242-262 Sentence denotes EXPERIMENTAL DESIGN:
TextSentencer_T5 263-518 Sentence denotes We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 BRCA mutation carriers and 806 noncarriers.
TextSentencer_T6 519-728 Sentence denotes Kruskal-Wallis tests were used to compare age of diagnosis and Gleason score, and logistic regression models were used to determine associations between carrier status, prostate cancer risk, and Gleason score.
TextSentencer_T7 729-825 Sentence denotes Hazard ratios (HR) for clinical end points were estimated using Cox proportional hazards models.
TextSentencer_T8 826-1136 Sentence denotes RESULTS: BRCA2 mutations were associated with a 3-fold risk of prostate cancer [odds ratio, 3.18; 95% confidence interval (95% CI), 1.52-6.66; P = 0.002] and presented with more poorly differentiated (Gleason score > or =7) tumors (85% versus 57%; P = 0.0002) compared with non-BRCA-associated prostate cancer.
TextSentencer_T9 1137-1181 Sentence denotes BRCA1 mutations conferred no increased risk.
TextSentencer_T10 1182-1567 Sentence denotes After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers.
TextSentencer_T11 1568-1761 Sentence denotes CONCLUSIONS: BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course.
TextSentencer_T12 1762-1877 Sentence denotes These results may have implications for tailoring clinical management of this subset of hereditary prostate cancer.
T1 0-77 Sentence denotes Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
T2 78-86 Sentence denotes PURPOSE:
T3 87-241 Sentence denotes Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined.
T4 242-262 Sentence denotes EXPERIMENTAL DESIGN:
T5 263-518 Sentence denotes We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 BRCA mutation carriers and 806 noncarriers.
T6 519-728 Sentence denotes Kruskal-Wallis tests were used to compare age of diagnosis and Gleason score, and logistic regression models were used to determine associations between carrier status, prostate cancer risk, and Gleason score.
T7 729-825 Sentence denotes Hazard ratios (HR) for clinical end points were estimated using Cox proportional hazards models.
T8 826-1136 Sentence denotes RESULTS: BRCA2 mutations were associated with a 3-fold risk of prostate cancer [odds ratio, 3.18; 95% confidence interval (95% CI), 1.52-6.66; P = 0.002] and presented with more poorly differentiated (Gleason score > or =7) tumors (85% versus 57%; P = 0.0002) compared with non-BRCA-associated prostate cancer.
T9 1137-1181 Sentence denotes BRCA1 mutations conferred no increased risk.
T10 1182-1567 Sentence denotes After 7,254 person-years of follow-up, and adjusting for clinical stage, prostate-specific antigen, Gleason score, and treatment, BRCA2 and BRCA1 mutation carriers had a higher risk of recurrence [HR (95% CI), 2.41 (1.23-4.75) and 4.32 (1.31-13.62), respectively] and prostate cancer-specific death [HR (95% CI), 5.48 (2.03-14.79) and 5.16 (1.09-24.53), respectively] than noncarriers.
T11 1568-1761 Sentence denotes CONCLUSIONS: BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course.
T12 1762-1877 Sentence denotes These results may have implications for tailoring clinical management of this subset of hereditary prostate cancer.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 1581-1586 gene:675 denotes BRCA2
T1 1630-1645 disease:C0376358 denotes prostate cancer
T2 1581-1586 gene:675 denotes BRCA2
T3 1630-1645 disease:C0600139 denotes prostate cancer
R1 T0 T1 associated_with BRCA2,prostate cancer
R2 T2 T3 associated_with BRCA2,prostate cancer

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 97-112 HP_0012125 denotes prostate cancer
T2 106-112 HP_0002664 denotes cancer

Allie

Id Subject Object Predicate Lexical cue
SS1_20215531_6_0 729-742 expanded denotes Hazard ratios
SS2_20215531_6_0 744-746 abbr denotes HR
AE1_20215531_6_0 SS1_20215531_6_0 SS2_20215531_6_0 abbreviatedTo Hazard ratios,HR

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
20215531-7#73#98#gene354 1255-1280 gene354 denotes prostate-specific antigen
20215531-7#140#145#gene672 1322-1327 gene672 denotes BRCA1
20215531-7#268#283#diseaseC0376358 1450-1465 diseaseC0376358 denotes prostate cancer
20215531-7#268#283#diseaseC0600139 1450-1465 diseaseC0600139 denotes prostate cancer
20215531-7#268#283#diseaseC0376358 1450-1465 diseaseC0376358 denotes prostate cancer
20215531-7#268#283#diseaseC0600139 1450-1465 diseaseC0600139 denotes prostate cancer
20215531-8#0#5#gene675 1581-1586 gene675 denotes BRCA2
20215531-8#49#64#diseaseC0376358 1630-1645 diseaseC0376358 denotes prostate cancer
20215531-8#49#64#diseaseC0600139 1630-1645 diseaseC0600139 denotes prostate cancer
73#98#gene354268#283#diseaseC0376358 20215531-7#73#98#gene354 20215531-7#268#283#diseaseC0376358 associated_with prostate-specific antigen,prostate cancer
73#98#gene354268#283#diseaseC0600139 20215531-7#73#98#gene354 20215531-7#268#283#diseaseC0600139 associated_with prostate-specific antigen,prostate cancer
73#98#gene354268#283#diseaseC0376358 20215531-7#73#98#gene354 20215531-7#268#283#diseaseC0376358 associated_with prostate-specific antigen,prostate cancer
73#98#gene354268#283#diseaseC0600139 20215531-7#73#98#gene354 20215531-7#268#283#diseaseC0600139 associated_with prostate-specific antigen,prostate cancer
140#145#gene672268#283#diseaseC0376358 20215531-7#140#145#gene672 20215531-7#268#283#diseaseC0376358 associated_with BRCA1,prostate cancer
140#145#gene672268#283#diseaseC0600139 20215531-7#140#145#gene672 20215531-7#268#283#diseaseC0600139 associated_with BRCA1,prostate cancer
140#145#gene672268#283#diseaseC0376358 20215531-7#140#145#gene672 20215531-7#268#283#diseaseC0376358 associated_with BRCA1,prostate cancer
140#145#gene672268#283#diseaseC0600139 20215531-7#140#145#gene672 20215531-7#268#283#diseaseC0600139 associated_with BRCA1,prostate cancer
0#5#gene67549#64#diseaseC0376358 20215531-8#0#5#gene675 20215531-8#49#64#diseaseC0376358 associated_with BRCA2,prostate cancer
0#5#gene67549#64#diseaseC0600139 20215531-8#0#5#gene675 20215531-8#49#64#diseaseC0600139 associated_with BRCA2,prostate cancer

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T318 1255-1280 gene:354 denotes prostate-specific antigen
T319 1450-1465 disease:C0376358 denotes prostate cancer
T320 1322-1327 gene:672 denotes BRCA1
T321 1581-1586 gene:675 denotes BRCA2
T322 1630-1645 disease:C0376358 denotes prostate cancer
R1 T318 T319 associated_with prostate-specific antigen,prostate cancer
R2 T318 T319 associated_with prostate-specific antigen,prostate cancer
R3 T320 T319 associated_with BRCA1,prostate cancer
R4 T320 T319 associated_with BRCA1,prostate cancer
R5 T321 T322 associated_with BRCA2,prostate cancer
R6 T321 T322 associated_with BRCA2,prostate cancer